11 Best Pharma Stocks to Buy According to Hedge Funds

7. Zoetis Inc. (NYSE:ZTS)

Number of Hedge Fund Holders: 76

Zoetis Inc. (NYSE:ZTS) is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health. Its operations are divided into the United States and International segments. Each segment boasts a diversified product portfolio, including vaccines, parasiticides, pain and sedation, animal health diagnostics, and more.

The company markets its products in around 45 countries across the globe and specializes in products across eight core species: companion animals (dogs, cats, and horses), cattle, swine, livestock (sheep and fish), and poultry. Zoetis Inc. (NYSE:ZTS) delivered 11% revenue growth in fiscal Q4 2024, reflecting the strength and demand of its brands and its continued focus on execution to drive broad-based growth. Revenue in the US grew by 11%, while international revenue increased by 10% operationally, marking significant revenue milestones for the company in a competitive landscape.

It also drove operational revenue growth in its companion animal portfolio and 5% operational revenue growth for its livestock portfolio. Zoetis Inc. (NYSE:ZTS) is confident about the ability of its growth drivers to drive sustainable growth in 2025, positioning it for continued above-market growth in the mid-to-high single-digit range for 2025 and beyond. The diversity of its business model with multiple growth drivers supports this optimism.